News

Biosite will have access to Compugen’s diagnostic and immunoassay biomarkers under a renewed and expanded partnership and licensing agreement.

Carl Zeiss has acquired the equipment business of the US Company Clarient to strengthen its clinical cancer diagnostics and cancer research.

Medical College of Georgia researchers will use a test to measure a tumor's aggressiveness in more than 10,000 women to identify the patients who need chemotherapy.

Opaldia has launched the programme incorporating genetic testing, screening and information services to help patients make informed decisions on breast cancer concerns.

Senior scientist Dr Mike Gresser, with experience at Amgen and Merck will assist the drive to develop new personalised medicines.

Monogram announces 20 presentations related to its portfolio of HIV diagnostic assays at the 14th Annual Conference on Retroviruses and Opportunistic Infections.

Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing diagnostic tests for metabolic diseases.

Both Companies in collaboration have developed a platform for customers in the diagnostics industry to test solutions based on Magnisense's MIAtek™ technology.

Galapagos' service division to provide lead optimization services for a University of Bristol research program focusing on destroying cancer cells in a contract valuing €2 million over two years.

CytoCore notes a market report projecting 41 percent annual growth in the area of molecular diagnostics and screening in the United States alone, with a market potential of $92 billion projected by 2016.